The University of Virginia is conducting a clinical research study for adults ages 18 and over who have untreated, unresectable or metastatic melanoma. The purpose of this study is to see how lifileucel (study treatment) plus a treatment called pembrolizumab is as good, the same, better or worse than treating your type of cancer with pembrolizumab. Lifileucel is a type of medicine known as immunotherapy, that uses your body’s immune system to fight cancer.

The University of Virginia seeks adults ages 18 and over with Recurrent Endometrial and/or Ovarian Cancer with an ARID1A Mutation for a research study of an investigational treatment.

The University of Virginia seeks adults ages 18 and over with locally advanced or metastatic resistant or refractory solid tumors harboring either CCNE1 amplification or a deleterious mutation in either FBXW7 or PPP2R1A, or other mutation with mechanistic rationale.
The primary goals of this study are:

The University of Virginia seeks patients ages 18 and over with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) for a research study.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have extensive stage small cell lung cancer. The purpose of this study is to see if the study drug, called alisertib, can help people with extensive stage small cell lung cancer. The study will also look at how well people tolerate treatment with alisertib.

As part of this study, you will take 50 mg alisertib by mouth, twice daily on Days 1 to 7 of every 21-day cycle.

The University of Virginia is conducting a clinical research study sponsored by the National Cancer Institute for adults ages 18 and over. These individuals should have solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials.

The Department of Public Health Sciences is conducting a research study comparing two web-based programs to help people drink fewer sugary drinks.

What Does the Study Include?
• The study lasts 18 months and, if you decide to join, you will be randomized (like a flip of a coin) into one of the two web-based programs
• You will complete the nine-week web-based program you are assigned and complete four 90-minute health assessments

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been diagnosed with relapsed or refractory Langerhans cell histiocytosis. This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory).

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric and young adult patients who are receiving Acute Lymphoblastic Leukemia therapy. This phase III trial compares the effect of adding levocarnitine to chemotherapy versus chemotherapy alone in protecting the liver in patients with leukemia and lymphoma. Standard of care chemotherapy treatment for leukemia and lymphoma includes a type of chemotherapy named asparaginase, given either as the drug pegaspargase, or a similar drug, calaspargase pegol.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (R/R CCA) to participate in a research study. The study will evaluate an investigational drug called tinengotinib as a possible treatment for R/R CCA. Tinengotinib is considered an investigational drug for use in this study because it has not been approved by the FDA.